Cytokinetics Incorporated recorded a cumulative net loss of $-894 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 257 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3828, from total ranking in previous quarter at 4428.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CYTK Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,328,383	-1,232,704	-1,166,352	-1,117,302	-900,908
CYTK's Total Ranking	# 3828	# 4428	# 3972	# 3953	# 4010
Seq. Net Income Change	-	-	-	-	-

CYTK Company Profile >> Back to CYTK Efficiency Comparisons >> Compare CYTK Net Income per Employee to its Competitors

CYTK Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 258
Healthcare Sector	# 654
Overall Market	# 3828

Net Income per Employee Statistics
High	Average	Low
$ 24,447	$ -334,809	$ -1,328,383
(Dec 31 2016)		(Jun 30 2026)

News about Cytokinetics Incorporated Income per employee

Cytokinetics Faces Financial Challenges with Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced its plans for an underwritten public offering of approximately $500 million worth of shares of its common stock. However, the company is currently struggling with a cumulative net loss of $527 million during the 12-month period ending in the third quarter of 2023. Additionally, within the Major Pharmaceutical Preparations industry, Cytokinetics has experienced a deterioration in its overall ranking when compared to the second quarter of 2023. This article will analyze the facts surrounding these announcements and assess their impact on the company s future prospects.
Analyzing the Facts:
Cytokinetics Proposed Public Offering:
Cytokinetics intends to sell shares of its common stock in an underwritten public offering, with an estimated value of approximately $500 million. However, the offering is subject to market conditions and other factors, making it uncertain whether or when it will be completed, as well as the final terms and size of the offering.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-08T01:13:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.